Current Report Filing (8-k)
May 21 2019 - 10:28AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported)
May
21, 2019
Wize Pharma, Inc.
(Exact Name of Registrant as Specified in its
Charter)
|
Delaware
|
|
000-52545
|
|
88-0445167
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
5b Hanagar Street, Hod Hasharon, Israel
|
|
4527708
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code:
+(972) 72-260-0536
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act
|
|
|
|
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
|
|
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
|
|
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Securities
registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Item 7.01.
|
Regulation FD Disclosure.
|
On
May 21, 2019, Wize Pharma, Inc. (the “Company”)
issued a letter to its
shareholders. A copy of the letter is furnished as Exhibit 99.1 hereto, and incorporated herein by reference.
In
accordance with General Instruction B.2 of Form 8-K, the information furnished pursuant to this Item 7.01, and including
Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (“Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in any such
filing.
The Securities and Exchange
Commission encourages registrants to disclose forward-looking information so that investors can better understand the future prospects
of a registrant and make informed investment decisions. This Current Report on Form 8-K and exhibits may contain these types of
statements, which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act
of 1995, and which involve risks, uncertainties and reflect the Registrant’s judgment as of the date of this Current Report
on Form 8-K. Forward-looking statements may relate to, among other things, operating results and are indicated by words or phrases
such as “expects,” “should,” “will,” and similar words or phrases. These statements are subject
to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of
this Current Report on Form 8-K. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information
presented within.
|
Item 9.01.
|
Financial Statement and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
Wize Pharma, Inc.
|
|
|
|
|
|
Date: May 21, 2019
|
By:
|
/s/ Or Eisenberg
|
|
|
|
Name:
|
Or Eisenberg
|
|
|
|
Title:
|
Chief Financial Officer
|